Cargando…
Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Autores principales: | Li, Maohua, Zhao, Rongqing, Chen, Jianxin, Tian, Wenzhi, Xia, Chenxi, Liu, Xudong, Li, Yingzi, Li, Song, Sun, Hunter, Shen, Tong, Ren, Wenlin, Sun, Le |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960786/ https://www.ncbi.nlm.nih.gov/pubmed/35347180 http://dx.doi.org/10.1038/s41598-022-09081-4 |
Ejemplares similares
-
Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2021) -
Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy
por: Zhao, Rongqing, et al.
Publicado: (2020) -
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023) -
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021) -
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)